<DOC>
	<DOCNO>NCT02199444</DOCNO>
	<brief_summary>The accumulation p-cresol , product metabolism aromatic aminoacid operate resident intestinal bacteria increase cardiovascular risk chronic kidney disease ( CKD ) patient . Therefore , therapeutic strategy reduce plasma p-cresol level highly demand . It report phosphate binder sevelamer sequesters p-cresol vitro , vivo study dialysis patient show controversial result . Aim study evaluate effect sevelamer p-cresol level CKD patient .</brief_summary>
	<brief_title>Effect Sevelamer P-cresol Levels CKD</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>age &gt; 18 year , CKD stage 35 Existing previous treatment within last 1 year phosphate binder ; hyperphosphatemia ( &gt; 5.6 mg/dL ) ; hypophosphatemia ( &lt; 2.5 mg/dL ) ; malnutrition , malignant neoplasm , current history gastrointestinal and/or endocrine disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>